Prolium is a biotechnology company, which specializes in providing breakthrough therapies to the patients with autoimmune diseases.
Prolium has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Prolium's investors include RTW Investments.
Prolium is headquartered in New York, United States.
Prolium is a biotechnology company, which specializes in providing breakthrough therapies to the patients with autoimmune diseases.
Prolium is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prolium — Funding & Investors." VCBacked, March 3, 2026, https://www.vcbacked.co/company/prolium. Accessed October 2, 2026.
VCBacked. (2026). Prolium — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/prolium
{{cite web |title=Prolium — Funding & Investors |url=https://www.vcbacked.co/company/prolium |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated